secwatch.observer — SEC 8-K summary
======================================

Issuer:     CorMedix Inc. (CRMD)
CIK:        0001410098
Form:       8-K
Filed at:   2026-01-08T23:59:59+00:00
Accession:  0001213900-26-002350
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CorMedix preliminary Q4 revenue ~$127M, FY2025 pro forma ~$400M; CEO becomes Chairman, new CCO appointed
--------------------------------------------------------------------------------

- Q4 2025 unaudited net revenue ~$127M; FY2025 pro forma net rev. ~$400M (incl. Melinta).
- Q4 adjusted EBITDA guidance $77-81M; cash & short-term investments ~$148M.
- FY2026 revenue guidance $300-320M; DefenCath rev. $150-170M; adj. EBITDA $100-125M.
- CEO Todisco salary raised to $750k (from $665k); target bonus to 75% (from 65%); assumes Chairman role.
- Appoints Mike Seckler as EVP & CCO; Phase 3 ReSPECT data expected Q2 2026; Analyst Day Feb 10.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1410098/000121390026002350/0001213900-26-002350-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1410098/000121390026002350/ea0272149-8k_cormedix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-002350

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer